Elisabeth I Heath1, Lance K Heilbrun2, Daryn Smith2, William M Schopperle3, Yawen Ju3, Susan Bolton2, Quratulain Ahmed4, Wael A Sakr4. 1. Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, U.S.A. heathe@karmanos.org. 2. Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, U.S.A. 3. CureMeta LLC, Boston, MA, U.S.A. 4. Department of Pathology, Wayne State University School of Medicine, Detroit, MI, U.S.A.
Abstract
BACKGROUND/AIM: Podocalyxin, a member of the CD34 family of cell surface sialomucins, is overexpressed in human embryonal carcinoma cell lines, as well as in several cancer types, and is associated with poor prognosis. Podocalyxin variants are associated with an increased risk and aggressiveness of prostate cancer. Herein podocalyxin protein expression in prostate cancer was characterized. MATERIALS AND METHODS: Expression of podocalyxin as well as of TRA-1-60 and TRA-1-81 antigens was assessed immunohistochemically in 84 radical prostatectomy specimens and in adjacent normal tissues. RESULTS: Podocalyxin expression and H-scores were considerably higher in prostate tumors compared to normal tissues. High TRA-1-60 and TRA-1-81 staining was detected, however, in a much smaller percentage of prostate tumors, while their expression and H-scores were low in normal tissues. Similar trends for all three proteins were observed in prostatic intraepithelial neoplasia. CONCLUSION: Overexpression of podocalyxin in prostate cancer renders the protein a putative immunohistochemical marker of prostate cancer that may contribute to stratification of patients for optimal treatment. Copyright
BACKGROUND/AIM: Podocalyxin, a member of the CD34 family of cell surface sialomucins, is overexpressed in humanembryonal carcinoma cell lines, as well as in several cancer types, and is associated with poor prognosis. Podocalyxin variants are associated with an increased risk and aggressiveness of prostate cancer. Herein podocalyxin protein expression in prostate cancer was characterized. MATERIALS AND METHODS: Expression of podocalyxin as well as of TRA-1-60 and TRA-1-81 antigens was assessed immunohistochemically in 84 radical prostatectomy specimens and in adjacent normal tissues. RESULTS:Podocalyxin expression and H-scores were considerably higher in prostate tumors compared to normal tissues. High TRA-1-60 and TRA-1-81 staining was detected, however, in a much smaller percentage of prostate tumors, while their expression and H-scores were low in normal tissues. Similar trends for all three proteins were observed in prostatic intraepithelial neoplasia. CONCLUSION: Overexpression of podocalyxin in prostate cancer renders the protein a putative immunohistochemical marker of prostate cancer that may contribute to stratification of patients for optimal treatment. Copyright
Authors: Uma R Chandran; Changqing Ma; Rajiv Dhir; Michelle Bisceglia; Maureen Lyons-Weiler; Wenjing Liang; George Michalopoulos; Michael Becich; Federico A Monzon Journal: BMC Cancer Date: 2007-04-12 Impact factor: 4.430
Authors: Catherine L Forse; Yildiz E Yilmaz; Dushanthi Pinnaduwage; Frances P O'Malley; Anna Marie Mulligan; Shelley B Bull; Irene L Andrulis Journal: Breast Cancer Res Treat Date: 2013-01-04 Impact factor: 4.872
Authors: Aruna Somasiri; Julie S Nielsen; Nikita Makretsov; Marcia L McCoy; Leah Prentice; C Blake Gilks; Stephen K Chia; Karen A Gelmon; David B Kershaw; David G Huntsman; Kelly M McNagny; Calvin D Roskelley Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: K Boman; A H Larsson; U Segersten; E Kuteeva; H Johannesson; B Nodin; J Eberhard; M Uhlén; P-U Malmström; K Jirström Journal: Br J Cancer Date: 2013-05-07 Impact factor: 7.640
Authors: Kimberly A Snyder; Michael R Hughes; Bradley Hedberg; Jill Brandon; Diana Canals Hernaez; Peter Bergqvist; Frederic Cruz; Kelvin Po; Marcia L Graves; Michelle E Turvey; Julie S Nielsen; John A Wilkins; Shaun R McColl; John S Babcook; Calvin D Roskelley; Kelly M McNagny Journal: Breast Cancer Res Date: 2015-03-27 Impact factor: 6.466
Authors: Julia Fröse; Michelle B Chen; Katie E Hebron; Ferenc Reinhardt; Cynthia Hajal; Andries Zijlstra; Roger D Kamm; Robert A Weinberg Journal: Cell Rep Date: 2018-07-24 Impact factor: 9.423
Authors: Jordan M White; Akhila N Kuda-Wedagedara; Madison N Wicker; Daniel E Spratt; William M Schopperle; Elisabeth Heath; Nerissa T Viola Journal: Mol Pharm Date: 2020-02-28 Impact factor: 4.939